Clinical Trial Update: A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations [Phase 1, Phase 2]

View source ↗

Summary

Pfizer studied lorlatinib (PF-06463922), an ALK/ROS1 inhibitor, in patients with advanced non-small cell lung cancer harboring ALK or ROS1 alterations. The Phas…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• lorlatinib (lorlatinib)

Snippet

Sponsor: Pfizer | Conditions: ALK-positive Non Small Cell Lung Cancer (NSCLC) and ROS1-positive NSCLC | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2018-05-29